Clinical Trial

Impact of Health Education on Knowledge, Attitude and Practice of Post-exposure Prophylaxis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 9, 2026 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Occupational exposure to blood-borne pathogens, such as human immune-deficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) for healthcare workers through contact with human blood and body fluids has become a major health concern as it poses a risk of transmission of these infectious agents. According to the World Health Organization (WHO) report, about three million HCWs are exposed to blood-borne pathogens each year, of which 170,000 are exposed to HIV infections, 2 million to HBV infections, and 0.9 million to HCV infections. Most of the time, healthcare providers get exposure through the splash of blood or other body fluids into the eyes, nose, or mouth or nonintact skin exposure, and percutaneous injury occurs as a result of a break in the skin caused by a needlestick or sharps contaminated with blood or body fluids
Trial Details
NCT Number NCT07330427
Lead Sponsor Aswan University
Conditions Post Exposure Prophylaxis
Enrollment 340 participants
Start Date 2025-06-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-09